Public Market Listing
4523 TSE
TSE primary exchange listing
External market data link · No third-party exchange redistribution
Assets (18 total) 18 Total Assets
10 Approved
3 Phase 3 / Filed
5 Phase 1–2 / Early
15 Diseases
Disease: All diseases (18) Alzheimer's Disease (4) Epilepsy (3) Non-Small Cell Lung Cancer (3) Breast Cancer (2) Parkinson's Disease (1) Helicobacter pylori Infection (1) Migraine (1) Developmental and Epileptic Encephalopathies (1) Lennox-Gastaut Syndrome (1) Rheumatoid Arthritis (1) Type 2 Diabetes (1) Small Cell Lung Cancer (1) Gastric Cancer (1) Colorectal Cancer (1) Ovarian Cancer (1)
Stage: All stages (18) Approved / Phase 4 (10) Phase 3 / Filed (3) Phase 2 Phase 1 / Preclinical
Quick filter: All (18) Alzheimer's Disease (4) Epilepsy (3) Non-Small Cell Lung Cancer (3) Breast Cancer (2) Parkinson's Disease (1)
Showing 18 of 18 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Approved Acetylcholinesterase Small molecule
Approved COMT Small molecule
Approved Tubulin / microtubules Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer Approved Amyloid-beta (monoclonal antibody) Monoclonal antibody
Approved AMPA receptor (antagonist) Small molecule
Epilepsy
Focal Onset Seizures, Primary Generalized Tonic-Clonic Seizures Approved H+/K+-ATPase (gastric proton pump) Small molecule
Helicobacter pylori Infection
Approved CGRP receptor Small molecule
Approved Voltage-gated sodium channel Small molecule
Epilepsy Developmental and Epileptic Encephalopathies Lennox-Gastaut Syndrome
Approved ROS1 Small molecule
Non-Small Cell Lung Cancer
ROS1-Positive Non-Small Cell Lung Cancer Approved Voltage-gated sodium channels Small molecule
Phase 3 NF-kB
Phase 3 SUR1 (short-acting) Small molecule
Phase 3 PD-1 Monoclonal antibody
Non-Small Cell Lung Cancer Small Cell Lung Cancer Gastric Cancer
Phase 2/3 Tau (monoclonal antibody) Monoclonal antibody
Phase 2 Orexin receptor (repositioned) Small molecule
Show all 18 assets (3 more) ↓ Upcoming events (19 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (3) November 2026 (1) December 2026 (2) 2027 (7) March 2027 (2) stenoparib Phase 2 Advanced Ovarian Cancer Est. primary completion 2027-03 ·
NCT03878849 ·
CT.gov ↗ What to watch
April 2027 (1) Perampanel · Fycompa Phase 2 Pediatric Epileptic Syndrome, Partial-onset Seizures Est. primary completion 2027-04-06 ·
NCT04015141 ·
CT.gov ↗ What to watch
May 2027 (1) Serplulimab Phase 2 Breast Cancer (Triple Negative Breast Cancer (TNBC)) Est. primary completion 2027-05-15 ·
NCT07487519 ·
CT.gov ↗ What to watch
June 2027 (1) Serplulimab Phase 2 Non Small Cell Lung Cancer, Small Cell Lung Cancer Est. primary completion 2027-06-18 ·
NCT07253142 ·
CT.gov ↗ What to watch
July 2027 (1) Serplulimab Phase 1/2 Colon Cancer Adenocarcinoma Est. primary completion 2027-07-28 ·
NCT07358585 ·
CT.gov ↗ What to watch
December 2027 (1) Serplulimab Phase 2 Carcinoma of Head and/or Neck Est. primary completion 2027-12-30 ·
NCT06857279 ·
CT.gov ↗ What to watch
2028 (2) October 2028 (1) December 2028 (1) Lecanemab · Leqembi Phase 3 Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease Est. primary completion 2028-12-21 ·
NCT04468659 ·
CT.gov ↗ What to watch
2029 (3) January 2029 (2) Taletrectinib Phase 3 Non Small Cell Lung Cancer Est. primary completion 2029-01 ·
NCT06564324 ·
CT.gov ↗ What to watch
March 2029 (1) Est. primary completion 2029-03-27 ·
NCT05156398 ·
CT.gov ↗ What to watch
2030 (3) February 2030 (1) Est. primary completion 2030-02-26 ·
NCT06616194 ·
CT.gov ↗ What to watch
July 2030 (1) August 2030 (1) Taletrectinib Phase 3 Non-small Cell Lung Cancer (NSCLC) Est. primary completion 2030-08-30 ·
NCT07154706 ·
CT.gov ↗ What to watch
2031 (1) January 2031 (1) Serplulimab Phase 2/3 Squamous NSCLC Est. primary completion 2031-01 ·
NCT07318883 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (26) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
4 January 2027 FDA action date Taletrectinib FDA target action date for IBTROZI sNDA Recent
4 October 2026 FDA action date Lenvatinib FDA PDUFA date for LENVIMA plus WELIREG in RCC
16 September 2026 Approval Taletrectinib FDA approves IBTROZI supplemental application with updated duration of response 3 September 2026 Approval Lecanemab NMPA approves Leqembi subcutaneous formulation as initiation treatment in China September 2026 Approval Lecanemab Japan approves the LEQEMBI Pen subcutaneous formulation 24 August 2026 FDA action date Lecanemab FDA extends PDUFA date for LEQEMBI IQLIK starting dose sBLA to August 24, 2026 16 July 2026 Filing accepted Lemborexant EMA accepts the lemborexant marketing authorisation application for evaluation 13 July 2026 Approval Lecanemab FDA approves LEQEMBI IQLIK subcutaneous initiation dose in early Alzheimer's 2 July 2026 Filing accepted Lemborexant MHRA accepts the lemborexant marketing authorisation application for evaluation 29 June 2026 Filing accepted Taletrectinib UK MHRA validates taletrectinib MAA June 2026 Filing accepted Taletrectinib MHRA validates taletrectinib marketing authorisation application UK, MHRA · Nuvation Bio Inc. and Eisai ·
Source ↗ 24 May 2026 FDA action date Lecanemab PDUFA action date set for LEQEMBI IQLIK starting dose 6 May 2026 Filing accepted Taletrectinib FDA accepts sNDA for IBTROZI with updated duration of response data The 12 most recent of 25 past events are shown.
Financial reports Annual history (4 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY $5.4B $1.0B $1.5B — report ↗
View 3 more years Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $5.2B $1.1B $1.8B — report ↗ 2023-FY $5.1B — — — report ↗ 2022-FY $5.5B — — — report ↗